Tasly Pharmaceutical Group Co Ltd Total Liabilities
Tasly Pharmaceutical Group Co Ltd total liabilities. Based on the latest financial reports, Tasly Pharmaceutical Group Co Ltd (600535) has total liabilities worth CN¥2.09 Billion CNY (≈ $306.39 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Tasly Pharmaceutical Group Co Ltd to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Tasly Pharmaceutical Group Co Ltd (1999–2025)
Total liabilities of Tasly Pharmaceutical Group Co Ltd from 1999 to 2025. This chart illustrates how Tasly Pharmaceutical Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore how much of Tasly Pharmaceutical Group Co Ltd's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Tasly Pharmaceutical Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of Tasly Pharmaceutical Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fujian Sunner Development Co Ltd
SHE:002299
|
China | CN¥13.21 Billion |
|
Group 1 Automotive Inc
NYSE:GPI
|
USA | $-15.30 Million |
|
GEPIC Energy Development Co Ltd
SHE:000791
|
China | CN¥21.07 Billion |
|
New Hope Corporation Ltd
AU:NHC
|
Australia | AU$894.41 Million |
|
Graphic Packaging Holding Company
NYSE:GPK
|
USA | $8.44 Billion |
|
Xi an Bright Laser Tech Co Ltd
SHG:688333
|
China | CN¥3.67 Billion |
|
SunocoCorp LLC
NYSE:SUNC
|
USA | $21.95 Billion |
|
Adaro Minerals Indonesia Tbk PT
JK:ADMR
|
Indonesia | Rp891.42 Million |
Liability Composition Analysis (1999–2025)
This chart breaks down Tasly Pharmaceutical Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 600535 total asset value.
Liquidity & Leverage Metrics
Tasly Pharmaceutical Group Co Ltd Total Liabilities Ratios Explained
Tasly Pharmaceutical Group Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tasly Pharmaceutical Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tasly Pharmaceutical Group Co Ltd (1999–2025)
The table below shows the annual total liabilities of Tasly Pharmaceutical Group Co Ltd from 1999 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥2.79 Billion ≈ $408.56 Million |
-2.55% |
| 2024-12-31 | CN¥2.87 Billion ≈ $419.25 Million |
-28.80% |
| 2023-12-31 | CN¥4.02 Billion ≈ $588.88 Million |
+5.92% |
| 2022-12-31 | CN¥3.80 Billion ≈ $555.97 Million |
+17.71% |
| 2021-12-31 | CN¥3.23 Billion ≈ $472.33 Million |
-21.45% |
| 2020-12-31 | CN¥4.11 Billion ≈ $601.34 Million |
-66.18% |
| 2019-12-31 | CN¥12.15 Billion ≈ $1.78 Billion |
-12.99% |
| 2018-12-31 | CN¥13.96 Billion ≈ $2.04 Billion |
+11.20% |
| 2017-12-31 | CN¥12.56 Billion ≈ $1.84 Billion |
+40.78% |
| 2016-12-31 | CN¥8.92 Billion ≈ $1.31 Billion |
+15.75% |
| 2015-12-31 | CN¥7.71 Billion ≈ $1.13 Billion |
-1.87% |
| 2014-12-31 | CN¥7.85 Billion ≈ $1.15 Billion |
+29.40% |
| 2013-12-31 | CN¥6.07 Billion ≈ $888.04 Million |
+85.06% |
| 2012-12-31 | CN¥3.28 Billion ≈ $479.87 Million |
+14.74% |
| 2011-12-31 | CN¥2.86 Billion ≈ $418.24 Million |
+40.95% |
| 2010-12-31 | CN¥2.03 Billion ≈ $296.72 Million |
+9.36% |
| 2009-12-31 | CN¥1.85 Billion ≈ $271.33 Million |
+36.82% |
| 2008-12-31 | CN¥1.36 Billion ≈ $198.31 Million |
+21.04% |
| 2007-12-31 | CN¥1.12 Billion ≈ $163.83 Million |
-27.29% |
| 2006-12-31 | CN¥1.54 Billion ≈ $225.32 Million |
+29.45% |
| 2005-12-31 | CN¥1.19 Billion ≈ $174.06 Million |
+43.94% |
| 2004-12-31 | CN¥826.42 Million ≈ $120.93 Million |
+43.54% |
| 2003-12-31 | CN¥575.74 Million ≈ $84.25 Million |
+126.94% |
| 2002-12-31 | CN¥253.70 Million ≈ $37.12 Million |
-27.14% |
| 2001-12-31 | CN¥348.19 Million ≈ $50.95 Million |
+31.82% |
| 2000-12-31 | CN¥264.15 Million ≈ $38.65 Million |
+22.69% |
| 1999-12-31 | CN¥215.29 Million ≈ $31.50 Million |
-- |
About Tasly Pharmaceutical Group Co Ltd
Tasly Pharmaceutical Group Co., Ltd, together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in China. The company offers prescription drugs covering various therapeutic areas, including cardiovascular-cerebrovascular, tumor immunity, digestion and metabolism, and neuroscience; over-the-counter drugs; modern TCM; biological drugs; and chemical… Read more